Core Viewpoint - Kanglong Chemical experienced a decline in stock price by 2.03% on October 17, 2023, with a current price of 30.45 CNY per share and a total market capitalization of 54.146 billion CNY [1] Group 1: Stock Performance - Year-to-date, Kanglong Chemical's stock price has increased by 19.41%, but it has seen a decline of 7.95% over the last five trading days and 6.22% over the last twenty days [1] - The stock's performance over the last sixty days shows an increase of 15.30% [1] Group 2: Financial Performance - For the first half of 2025, Kanglong Chemical reported a revenue of 6.441 billion CNY, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 701 million CNY [2] - Since its A-share listing, the company has distributed a total of 1.794 billion CNY in dividends, with 1.007 billion CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kanglong Chemical increased by 10.12% to 87,900 [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3] Group 4: Business Overview - Kanglong Chemical, established on July 1, 2004, and listed on January 28, 2019, specializes in drug research, development, and production services [1] - The company's revenue composition includes laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1]

Group 1 - A-shares and Hong Kong stocks in the innovative pharmaceutical sector have rebounded, with significant gains in related stocks and ETFs [1][3][5] - The largest medical ETF in A-shares (512170) saw a trading volume of 589 million yuan, recovering 1.34% on the day [1] - The innovative drug sector is experiencing a collective rise, with notable stocks like Huahai Pharmaceutical increasing by 7.59% [3] Group 2 - The Hong Kong innovative drug ETF (520880) rose by 2.12%, with 35 out of 37 constituent stocks gaining, led by Green Leaf Pharmaceutical with an 8.31% increase [5][7] - Recent funding trends indicate a significant inflow into the innovative drug sector, with over 1.29 billion yuan added in the last three days [7] - Upcoming catalysts include the European Society for Medical Oncology (ESMO) annual meeting, which may showcase significant research results from Chinese innovative drugs [7] Group 3 - Investment strategies suggest focusing on innovative drugs, with specific ETFs like the Hong Kong innovative drug ETF (520880) and the A-share drug ETF (562050) highlighted for their potential [8] - The medical ETF (512170) is noted for its inclusion of CXO companies, which account for 26.77% of its weight [8] - The medical ETF is the largest in the market, with a scale of 26.4 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9]

Core Viewpoint - 康龙化成's stock increased by 4.33% on October 15, with a trading volume of 9.50 billion and a market capitalization of 557.46 billion [1] Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to drug development [2][7] - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7] Financial Performance - For the first half of 2025, 康龙化成 achieved a revenue of 64.41 billion, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 7.01 billion [8] - The company has distributed a total of 17.94 billion in dividends since its A-share listing, with 10.07 billion distributed in the last three years [9] Market Position and Trends - 康龙化成 is a leader in the CRO (Contract Research Organization) sector, providing comprehensive CRMO solutions for drug discovery and development, focusing on small molecule drug research [2] - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 84.95% of total revenue [3] Digital Transformation and Innovation - 康龙化成 has made significant progress in digital and intelligent construction within its clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through AI and automation [3] - The integration of AI technology is expected to improve clinical service efficiency and reduce labor costs, although there may be risks related to management and technology integration [2][3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） 中華人民共和國，北京 2025年10月14日 （股份代號：3759） 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年10月28日（星期二）舉行，藉以（其中包括）審議及批 准本公司及其附屬公司截至2025年9月30日止九個月之第三季度業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 樓柏良博士 ...

Core Viewpoint - 康龙化成 (03759.HK) will hold a board meeting on October 28, 2025, to review and approve the third-quarter results for the nine months ending September 30, 2025 [1] Group 1 - The board meeting is scheduled for October 28, 2025 [1] - The meeting will focus on the financial performance of the company and its subsidiaries [1] - The results to be reviewed will cover the period ending September 30, 2025 [1]

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年10月28日（星期二）舉行，藉以（其中包括）審議及批 准本公司及其附屬公司截至2025年9月30日止九個月之第三季度業績。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 中華人民共和國，北京 2025年10月14日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are Green Power Environmental (70.05%), China Telecom (69.96%), and COSCO Shipping Energy (68.73%) [1][2] - The companies with the largest increase in holding amounts over the last five trading days are Zijin Mining (+1 billion), Kuaishou (+0.981 billion), and Pop Mart (+0.624 billion) [1][2] - The companies with the largest decrease in holding amounts over the last five trading days are SMIC (-2.258 billion), Hua Hong Semiconductor (-1.222 billion), and Alibaba (-0.714 billion) [1][4] Hong Kong Stock Connect Holding Ratios - Green Power Environmental (01330) has a holding of 283 million shares, representing 70.05% [2] - China Telecom (00728) has a holding of 9.711 billion shares, representing 69.96% [2] - COSCO Shipping Energy (01138) has a holding of 891 million shares, representing 68.73% [2] - Other notable companies include Changfei Optical Fiber (06869) at 68.48% and China Shenhua (01088) at 67.25% [2] Recent Increases in Holdings - Zijin Mining (02899) saw an increase of 1 billion in holding amount, with a change of 29.19 million shares [2][4] - Kuaishou (01024) experienced an increase of 0.981 billion, with a change of 12.19 million shares [2][4] - Pop Mart (09992) had an increase of 0.624 billion, with a change of 2.39 million shares [2][4] Recent Decreases in Holdings - SMIC (00981) had a decrease of 2.258 billion in holding amount, with a change of 28.18 million shares [4] - Hua Hong Semiconductor (01347) saw a decrease of 1.222 billion, with a change of 13.86 million shares [4] - Alibaba (09988) experienced a decrease of 0.714 billion, with a change of 4.39 million shares [4]

Group 1 - Hong Kong's Hang Seng Index fell by 3.49%, down 916 points, closing at 25,373 points, while the Hang Seng Tech Index dropped by 4.54%. The morning trading volume reached HKD 281.8 billion [1] - Jinli Permanent Magnet (06680) surged over 12% as a rare earth giant announced price increases, with institutions optimistic about the strengthening strategic position of rare earths [1] - Semiconductor stocks rose against the trend, with Huahong Semiconductor (01347) increasing by 3.6%, driven by escalating competition in the technology sector and multiple catalysts for the semiconductor industry [1] - Kingsoft (03888) saw a rise of over 18% at one point, closing up over 9%, as external frictions escalate, highlighting the trend towards self-controlled industries and investment opportunities in the Xinchuang sector [1] - Gold stocks mostly rose due to risk aversion, with spot gold breaking through USD 4,060. Zijin Mining International (02259) increased by 4.6%, and Chifeng Jilong Gold Mining (06693) rose by 2.5% [1] Group 2 - MicroPort Scientific-B (02252) rose over 2% as its commercialization process accelerated, with overseas orders exceeding 60 units [2] Group 3 - Liqin Resources (02245) increased by over 5% following the implementation of cobalt export quotas in the Democratic Republic of Congo [3] - China Merchants Energy (01138) rose over 4% due to seasonal demand and event disturbances, with institutions expecting stronger freight rates [3] - Domestic insurance stocks fell across the board, with Tianan Insurance announcing a debt default of CNY 5.3 billion, which institutions suggest may mark the beginning of market-driven risk pricing. New China Life Insurance (01336) fell by 5%, China Pacific Insurance (02328) by 3.9%, and China Taiping Insurance (02601) by 3.6% [3] Group 4 - Pharmaceutical stocks continued their recent downward trend, with Junshi Biosciences (01877) dropping nearly 10.6% and Kanglong Chemical (03759) falling over 9% [4] Group 5 - Apple-related stocks experienced significant declines, with Hongteng Precision (06088) dropping over 10%, as institutions stated that the impact of tariffs on the supply chain should not be overestimated [5]

Core Viewpoint - The Hong Kong pharmaceutical stocks continue to decline, particularly in the CRO sector, with significant drops in share prices for several companies [1] Group 1: Company Performance - Junshi Biosciences (01877.HK) decreased by 7.98%, trading at 27.22 HKD [1] - Kanglong Chemical (03759.HK) fell by 6.3%, with a price of 24.4 HKD [1] - Kelun Pharmaceutical (06821.HK) saw a decline of 5.69%, priced at 91.95 HKD [1] - Tigermed (03347.HK) dropped by 3.48%, trading at 42.4 HKD [1]

Group 1 - Pharmaceutical stocks continue to decline, with CRO sector leading the drop, including significant declines in Junshi Biosciences (down 7.98%), Kanglong Chemical (down 6.3%), Kelaiying (down 5.69%), and Tigermed (down 3.48%) [1] - Recent market trends in the pharmaceutical sector are attributed to several factors, including a deal between the Trump administration and Pfizer to lower drug prices in the U.S., which is seen as a reconciliation signal between U.S. pharmaceutical companies and the government [1] - The U.S. Senate's consideration of a bill to prohibit certain Chinese biotech companies from receiving federal funding has led to a significant pullback in the CXO sector [1] Group 2 - Recent tensions in U.S.-China trade relations have escalated, with a renewed tariff war expected; however, the pharmaceutical market is not overly concerned as the industry has shown resilience since the first tariff war in April [2] - The innovative drug and CXO sectors have outperformed other sub-industries, driven by China's rising independent innovation and ongoing overseas business development, which are less affected by tariffs [2] - The CXO sector benefits from strong upstream and downstream relationships and a service pricing model that allows companies to pass on tariff pressures relatively freely [2]